Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinyue capsule versus placebo after PCI in coronary heart disease
ChiCTR-IPR-14005475Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Apr 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xinyue Capsule in coronary arteriosclerosis (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: cardiac death, nonfatal acute myocardial infarction and 6 more. Started Apr 2014; status: recruiting.
02
Drugs
Xinyue Capsule
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-IPR-14005475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005475.